Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases

Decker, Paul; Moulinet, T.; López, Benjamín; Dubucquoi, Sylvain; Bonnotte, Bernard; Lakomy, Daniela; Revuz, Sabine; Luc, Amandine; Bittencourt, Marcelo De Carvalho; Hachulla, É.; Jaussaud, R.

doi:10.1016/j.ejim.2021.04.020

Cited by 17 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A higher OR shows that patients with positive anti-Ro52 were more likely to have simultaneous ILD. MCTD, mixed connective tissue disease; SLE, systemic lupus erythematosus 1–3 22–29 36 37 39–76…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis

Nayebirad,

Mohamadi,

Yousefi-Koma

et al. 2023

BMJ Open Resp Res

View full text Add to dashboard Cite

ObjectivesInterstitial lung disease (ILD) is an important manifestation of autoimmune diseases that can lead to morbidity and mortality. Although several autoantibodies have been linked with ILD presentation and adverse outcomes, the association of anti-Ro52 antibody with ILD is less studied. Hence, we investigated this association in various autoimmune diseases in the current study.DesignWe designed a systematic review and meta-analysis and did a comprehensive search from inception until 2 January 2023.Data sourcesA systematic search was conducted in four electronic databases: PubMed, Web of Science, Scopus and Embase.Eligibility criteriaObservational studies that reported ILD diagnosis (outcome) and anti-Ro antibody (exposure) status in any autoimmune conditions (population) were included. The association between rapidly progressive ILD (RP-ILD) and anti-Ro52 was studied in idiopathic inflammatory myopathies (IIM).Data extraction and synthesisCollected data included study characteristics and ORs with 95% CIs. Quality assessment was performed using a modified version of the Newcastle-Ottawa Scale for cross-sectional studies. Random effects meta-analysis was used to pool the effect estimates.ResultsA total of 2353 studies were identified, from which 59 articles met the eligibility criteria. Anti-Ro52/SSA positivity was associated with ILD in all autoimmune disease subgroups: IIM (OR=3.08; 95% CI: 2.18 to 4.35; p value<0.001; I2=49%), systemic lupus (OR=2.43; 95% CI: 1.02 to 5.79; p=0.046; I2=71%), Sjogren (OR=1.77; 95% CI: 1.09 to 2.87; p=0.021; I2=73%), systemic sclerosis (OR=1.71; 95% CI: 1.04 to 2.83; p=0.036; I2=43%), mixed connective tissue disease (OR=3.34; 95% CI: 1.82 to 6.13; p<0.001; I2=0%). Additionally, anti-Ro52-positive myopathy patients were more likely to have simultaneous RP-ILD (OR=2.69; 95% CI:1.50 to 4.83; p<0.001; I2=71%).ConclusionAnti-Ro52/SSA positivity is associated with a higher frequency of ILD diagnosis in various autoimmune diseases. Anti-Ro52/SSA is also linked with a more severe lung involvement (RP-ILD). Future studies can investigate the benefits of screening for anti-Ro52 and its association with ILD development.PROSPERO registration numberCRD42022381447.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Subgroup meta-analysis of articles with interstitial lung disease based on whether studies differentiated between anti-Ro52 and anti-SSA 1–3 22–24 27 36 37 39–51 54–57 63 65 66 68–72 74 76…”

Section: Resultsmentioning

confidence: 99%

Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis

Nayebirad,

Mohamadi,

Yousefi-Koma

et al. 2023

BMJ Open Resp Res

View full text Add to dashboard Cite

show abstract

“…SSc, MCTD, and SLE are the most common causes of CTD-associated PAH [ 44 ]. A high incidence of micro- or macroangiopathy including digital tip ulcers, distal ischemia, and PAH was previously reported in CTD patients with anti-Ro52, including in patients with SSc [ 45 ]. Lee et al [ 46 ] found that anti-Ro52 was independently associated with PAH and mortality in patients with SSc.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases

Yang

Hong

Guo

et al. 2023

Journal of Immunology Research

View full text Add to dashboard Cite

Objective. Anti-Ro60 and anti-Ro52 antibodies are associated with different connective tissue diseases (CTDs). However, the clinical significance of anti-Ro antibodies is not always consistent among different global regions. The aim of this study was to investigate the clinical characteristics of patients with anti-Ro antibodies. Methods. A total of 1596 inpatients with anti-Ro antibodies were included in the study. Demographic, clinical, and serological data were compared between individuals with different profiles of anti-Ro antibodies: patients with anti-Ro52 antibodies alone, patients with anti-Ro60 antibodies alone, and patients with combined anti-Ro52 and anti-Ro60 antibodies. Results. Of the 1596 patients, 1362 (85.3%) were female, the mean age was 45.5 years, and systemic lupus erythematosus (SLE) (46.0%) and Sjogren’s syndrome (SS) (19.0%) were the most common CTD diagnoses. Among the patients with anti-Ro52 antibodies alone, idiopathic inflammatory myopathy (18.8%) and SLE (17.6%) were the most common CTD diagnoses. The coexistent autoantibodies of this group were significantly lower compared with those of the other two groups, while the presence of anti-Jo1 antibodies were significantly higher compared with those of the other two groups (3.7% vs. 0.6% vs. 1.9%, p = 0.029 ). In addition, the patients with isolated anti-Ro52 antibodies were more likely to suffer from interstitial lung disease (35.5% vs. 11.3% vs. 13.7%, p < 10 − 4 ) and pulmonary arterial hypertension (10.1% vs. 5.3% vs. 3.6%, p = 0.001 ) compared with the other two groups of patients. Compared with patients with isolated anti-Ro52 or anti-Ro60 antibodies, the patients with combined anti-Ro52 and anti-Ro60 antibodies were more likely to suffer from xerophthalmia and xerostomia. Furthermore, hypocomplementemia, hyperglobulinemia, and proteinuria were particularly prevalent in patients with anti-Ro60 antibodies. Conclusion. Different profiles of anti-Ro antibodies were significantly associated with clinical phenotypic features in CTDs, indicating the potential diagnostic and prognostic value of these antibodies in clinical practice.

show abstract

“…Notably, the anti-Ro52 antibody is found in a significant proportion of ASyS patients and appears to correlate with the presence and severity of ILD ( 89 ). It is detected in concert with the aminoacyl tRNA synthetase antibodies on an extended myositis blot and may be informative in terms of prognosis and guiding initial treatment strategies as well as a surrogate marker of ASyS ( 90 ).…”

Section: Autoimmune Serologymentioning

confidence: 99%

A multidisciplinary approach to the diagnosis of antisynthetase syndrome

et al. 2022

View full text Add to dashboard Cite

Antisynthetase syndrome is a subtype of idiopathic inflammatory myopathy, strongly associated with the presence of interstitial lung disease. Diagnosis is made by identifying myositis-specific antibodies directed against aminoacyl tRNA synthetase, and relevant clinical and radiologic features. Given the multisystem nature of the disease, diagnosis requires the careful synthesis of subtle clinical and radiological features with the interpretation of specialized autoimmune serological testing. This is provided in a multidisciplinary environment with input from rheumatologists, respiratory physicians, and radiologists. Differentiation from other idiopathic interstitial lung diseases is key; treatment and prognosis differ between patients with antisynthetase syndrome and idiopathic interstitial lung disease. In this review article, we look at the role of the multidisciplinary team and its individual members in the initial diagnosis of the antisynthetase syndrome, including the role of physicians, radiologists, and the wider team.

show abstract

Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases

Cited by 17 publications

References 22 publications

Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis

Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis

Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases

A multidisciplinary approach to the diagnosis of antisynthetase syndrome

Contact Info

Product

Resources

About